Ad
CCXI Short Information ChemoCentryx Inc.
home / stock / ccxi / ccxi short
Short Information | ChemoCentryx Inc. (NASDAQ:CCXI)
| Twenty Trading Day Totals | |
|---|---|
| Total Shorted Volume | 1,230,458 |
| Total Actual Volume | 24,638,198 |
| Short Trends | |
|---|---|
| Cover Days | 20 |
| Short Days | 0 |
| No Change Days | 0 |
| Averages | |
|---|---|
| Average Short Volume | 61,523 |
| Average Short Percentage | 5.86% |
Is there a CCXI Short Squeeze or Breakout about to happen?
See the CCXI Short Analysis for free Sign up or Login
Powered by Squeeze Report
CCXI Twenty Trading Day's Volume to Short Volume Chart
CCXI Twenty Trading Day Price Chart
CCXI Short Data Results Days
| Date | Open | Close | High | Low | Total Volume | Short Volume | Short Percentage |
|---|---|---|---|---|---|---|---|
| 10-19-2022 | $51.98 | $51.99 | $52 | $51.98 | 2,480,366 | 104,654 | 4.22% |
| 10-18-2022 | $51.97 | $51.96 | $51.985 | $51.95 | 953,467 | 47,026 | 4.93% |
| 10-17-2022 | $51.94 | $51.98 | $51.98 | $51.93 | 733,281 | 24,429 | 3.33% |
| 10-14-2022 | $51.94 | $51.94 | $51.96 | $51.93 | 629,086 | 41,430 | 6.59% |
| 10-13-2022 | $51.91 | $51.94 | $51.95 | $51.9 | 933,386 | 48,730 | 5.22% |
| 10-12-2022 | $51.88 | $51.95 | $51.95 | $51.87 | 891,178 | 31,646 | 3.55% |
| 10-11-2022 | $51.84 | $51.92 | $51.92 | $51.84 | 846,625 | 56,455 | 6.67% |
| 10-10-2022 | $51.85 | $51.85 | $51.88 | $51.83 | 463,700 | 37,707 | 8.13% |
| 10-07-2022 | $51.83 | $51.86 | $51.88 | $51.82 | 715,881 | 81,026 | 11.32% |
| 10-06-2022 | $51.84 | $51.85 | $51.87 | $51.83 | 756,806 | 35,889 | 4.74% |
| 10-05-2022 | $51.82 | $51.89 | $51.9 | $51.78 | 723,027 | 42,758 | 5.91% |
| 10-04-2022 | $51.84 | $51.87 | $51.89 | $51.8 | 945,475 | 74,800 | 7.91% |
| 10-03-2022 | $51.7 | $51.82 | $51.88 | $51.66 | 1,250,809 | 55,578 | 4.44% |
| 09-30-2022 | $51.67 | $51.66 | $51.79 | $51.66 | 1,046,910 | 63,485 | 6.06% |
| 09-29-2022 | $51.68 | $51.66 | $51.74 | $51.6 | 1,837,071 | 82,649 | 4.5% |
| 09-28-2022 | $51.65 | $51.68 | $51.755 | $51.64 | 1,325,537 | 75,494 | 5.7% |
| 09-27-2022 | $51.65 | $51.64 | $51.77 | $51.5965 | 927,802 | 115,584 | 12.46% |
| 09-26-2022 | $51.63 | $51.62 | $51.76 | $51.61 | 1,351,664 | 81,846 | 6.06% |
| 09-23-2022 | $51.76 | $51.64 | $51.8 | $51.55 | 4,972,872 | 100,063 | 2.01% |
| 09-22-2022 | $51.78 | $51.78 | $51.795 | $51.76 | 853,255 | 29,209 | 3.42% |
News, Short Squeeze, Breakout and More Instantly...
Ad
-
AMGEN SUCCESSFULLY COMPLETES ACQUISITION OF CHEMOCENTRYX PR Newswire TAVNEOS ® (avacopan), a First-in-Class Medicine for Patients With Severe Active ANCA-Associated Vasculitis, Added to Inflammation Portfolio THOUSAND OAKS, Calif. , Oct. 20, ...
-
-- Planned posters and an oral presentation will highlight data from the trials that supported the approval of TAVNEOS ® (avacopan) for patients with ANCA-associated vasculitis; additional poster will cover expression of kidney C5aR -- SAN CARLOS, Calif., Oct. 17,...
-
-- Two poster presentations planned for CCX559, including results from ongoing Phase I clinical study in patients with advanced solid tumors, and preclinical evidence from murine model -- SAN CARLOS, Calif., Oct. 05, 2022 (GLOBE NEWSWIRE) -- ChemoCentryx, Inc., (Nasdaq: CCXI), tod...